Abcuro
Abcuro raises $200M Series C at $1.5B valuation
Quick Facts
Abcuro: Series C Funding Round
Abcuro has successfully raised $200M in Series C funding, reaching a valuation of $1.5B.
Company Overview
Antibody therapeutics for autoimmune diseases
Funding Details
The Series C round was led by RA Capital, with participation from Arch Venture Partners.
Company Information
- Headquarters: Cambridge, MA
- Founded: 2020
- Employees: 100+
- Category: HealthTech
Investment
Abcuro plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- RA Capital: Verified investor in Series C
- Arch Venture Partners: Verified investor in Series C
Key Investors
About the Author
Related Company Reports
Abridge Raises $150M Series C to Transform HealthTech
Abridge has secured $150M Series C in funding to accelerate growth and innovation in the healthtech sector. Medical AI scribe platform automatically documenting patient-provider conversations and generating clinical notes...
Innovaccer Raises $275M Series F to Transform HealthTech
Innovaccer has secured $275M Series F in funding to accelerate growth and innovation in the healthtech sector. Healthcare data platform unifying patient data and providing analytics for value-based care and population health manage...
Truveta Raises $95M Series B to Transform HealthTech
Truveta has secured $95M Series B in funding to accelerate growth and innovation in the healthtech sector. Healthcare data platform aggregating de-identified patient records to accelerate medical research and drug development...
